Use of monoclonal anti-C3 antibodies to characterise the fragments of C3 that are found on erythrocytes.
Using monoclonal antibodies to C3 it has been shown that the red blood cells of patients with cold haemagglutinin disease carry on their cells C3d,g (alpha-2D-globulin) rather than C3d. C3d,g seems to be the final product of in vivo C3 activation in fluid phase and on red cells. The cleavage of C3dg to C3d and C3g does not appear to occur in vivo either in the fluid phase or on red cell bound C3bi. In vitro C3-coated red cells prepared by antibody or low ionic strength techniques produce cells with C3d and C3bi as the predominant C3 fragment, whereas the Fruitstone technique in which coating occurs by the alternative pathway has principally C3b. The activity of C3 cleaving enzymes in whole serum is strongly influenced by the ionic conditions of the serum.
D000744:Anemia, Hemolytic, Autoimmune / Q000276:immunology*; D000911:Antibodies, Monoclonal; D003166:Complement Activating Enzymes / Q000276:immunology; D003167:Complement Activation; D003176:Complement C3 / Q000276:immunology*; D003179:Complement C3b / Q000276:immunology; D015933:Complement C3d; D004912:Erythrocytes / Q000276:immunology*; D006801:Humans; D011951:Receptors, Complement
D000911:Antibodies, Monoclonal; D003176:Complement C3; D011951:Receptors, Complement; C034772:complement C3g; D003179:Complement C3b; D015933:Complement C3d; D003166:Complement Activating Enzymes